세계 니코틴 대체요법 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 예측(2024-2032년)

The global demand for Nicotine Replacement Therapy Market is presumed to reach the market size of nearly USD 293.58 Billion by 2032 from USD 70.31 Billion in 2023 with a CAGR of 17.21% under the study period 2024 - 2032.

Nicotine replacement therapy (NRT) is the first pharmacological drug that was approved by the FDA for smoking cessation. Nicotine replacement therapy aims to reduce withdrawal symptoms which are often experienced during an attempt to quit smoking and thus increase the probability of remaining abstinent. Nicotine gums were the first product that was introduced in the early '80s followed by the nicotine patch in the early '90s and both became available over the counter (OTC) after few years. Then nicotine nasal spray was introduced by prescription, followed by the nicotine inhaler in the same year and now both them are available over the counter. Nicotine longezes/tablets were introduced, later on, they come in pill or candy-like tablet and are also available OTC. All these forms of delivery can be purchased by anyone at pharmacies, drug stores, and supermarkets.

Market Dynamics

The market of NRT is driven by the growing desire to quit smoking and the rising number of manufacturers offering anti-smoking campaigns and penetration of smoking cessation products. Other factors like growing cases of chronic obstructive pulmonary disease (COPD), asthma, lung cancer, asthma, various cardiac and respiratory disease coupled with rising awareness regarding negative effects of smoking is also set to support the market expansion over the forecast period.

The report covers Porter's Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level.

Additionally, these tools also give inclusive assessment of each application/product segment in the global market of nicotine replacement therapy.

Market Segmentation

The entire nicotine replacement therapy market has been sub-categorized into product type and distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.

By Product

• Nicotine Replacement Therapy (Inhalers, Gum, Transdermal Patches, Sublingual Tablets, Lozenges, Others)
• E-cigarettes
• Heat-not-burn Tobacco Products

By Distribution Channel

• Online
• Offline
• Regional Analysis

This section covers regional segmentation which accentuates on current and future demand for nicotine replacement therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Nicotine Replacement Therapy market include Cipla Inc., Pfizer Inc., Glenmark Pharmaceuticals Ltd., Fertin Pharma, Philip Morris Products S.A., British American Tobacco plc, Japan Tobacco Inc., Imperial Brands plc, Johnson & Johnson Private Limited. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. NICOTINE REPLACEMENT THERAPY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Distribution Channel
  • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL NICOTINE REPLACEMENT THERAPY MARKET ANALYSIS BY PRODUCT

• 5.1. Overview By Product
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Product
• 5.4. Nicotine Replacement Therapy (Inhalers, Gum, Transdermal Patches, Sublingual Tablets, Lozenges, Others) Historic and Forecast Sales By Regions
• 5.5. E-cigarettes Historic and Forecast Sales By Regions
• 5.6. Heat-not-burn tobacco products Historic and Forecast Sales By Regions

6. GLOBAL NICOTINE REPLACEMENT THERAPY MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 6.1. Overview By Distribution Channel
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Distribution Channel
• 6.4. Online Historic and Forecast Sales By Regions
• 6.5. Offline Historic and Forecast Sales By Regions

7. GLOBAL NICOTINE REPLACEMENT THERAPY MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2 North America By Segment Sales Analysis
  • 7.3.3 North America By Country Sales Analysis
  • 7.3.4 United States Sales Analysis
  • 7.3.5 Canada Sales Analysis
  • 7.3.6 Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2 Europe By Segment Sales Analysis
  • 7.4.3 Europe By Country Sales Analysis
  • 7.4.4 United Kingdom Sales Analysis
  • 7.4.5 France Sales Analysis
  • 7.4.6 Germany Sales Analysis
  • 7.4.7 Italy Sales Analysis
  • 7.4.8 Russia Sales Analysis
  • 7.4.9 Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2 Asia Pacific By Segment Sales Analysis
  • 7.5.3 Asia Pacific By Country Sales Analysis
  • 7.5.4 China Sales Analysis
  • 7.5.5 India Sales Analysis
  • 7.5.6 Japan Sales Analysis
  • 7.5.7 South Korea Sales Analysis
  • 7.5.8 Australia Sales Analysis
  • 7.5.9 South East Asia Sales Analysis
  • 7.5.10 Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2 Latin America By Segment Sales Analysis
  • 7.6.3 Latin America By Country Sales Analysis
  • 7.6.4 Brazil Sales Analysis
  • 7.6.5 Argentina Sales Analysis
  • 7.6.6 Peru Sales Analysis
  • 7.6.7 Chile Sales Analysis
  • 7.6.8 Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2 Middle East & Africa By Segment Sales Analysis
  • 7.7.3 Middle East & Africa By Country Sales Analysis
  • 7.7.4 Saudi Arabia Sales Analysis
  • 7.7.5 UAE Sales Analysis
  • 7.7.6 Israel Sales Analysis
  • 7.7.7 South Africa Sales Analysis
  • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE NICOTINE REPLACEMENT THERAPY COMPANIES

• 8.1. Nicotine Replacement Therapy Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9. COMPANY PROFILES OF NICOTINE REPLACEMENT THERAPY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Cipla Inc.
  • 9.3.1 Company Overview
  • 9.3.2 Company Revenue
  • 9.3.3 Products
  • 9.3.4 Recent Developments
• 9.4. Pfizer Inc.
  • 9.4.1 Company Overview
  • 9.4.2 Company Revenue
  • 9.4.3 Products
  • 9.4.4 Recent Developments
• 9.5. Glenmark Pharmaceuticals Ltd.
  • 9.5.1 Company Overview
  • 9.5.2 Company Revenue
  • 9.5.3 Products
  • 9.5.4 Recent Developments
• 9.6. Fertin Pharma
  • 9.6.1 Company Overview
  • 9.6.2 Company Revenue
  • 9.6.3 Products
  • 9.6.4 Recent Developments
• 9.7. Philip Morris Products S.A.
  • 9.7.1 Company Overview
  • 9.7.2 Company Revenue
  • 9.7.3 Products
  • 9.7.4 Recent Developments
• 9.8. British American Tobacco Plc
  • 9.8.1 Company Overview
  • 9.8.2 Company Revenue
  • 9.8.3 Products
  • 9.8.4 Recent Developments
• 9.9. Japan Tobacco Inc.
  • 9.9.1 Company Overview
  • 9.9.2 Company Revenue
  • 9.9.3 Products
  • 9.9.4 Recent Developments
• 9.10. Imperial Brands Plc
  • 9.10.1 Company Overview
  • 9.10.2 Company Revenue
  • 9.10.3 Products
  • 9.10.4 Recent Developments
• 9.11. Johnson & Johnson Private Limited
  • 9.11.1 Company Overview
  • 9.11.2 Company Revenue
  • 9.11.3 Products
  • 9.11.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies